August 16, 2022 04:48 PM EDT
R&D
Pharma

Ab­b­Vie calls off PhI tri­al for I-Mab’s CD47 days af­ter Zai Lab shelves its own pro­gram

Kyle LaHucik

Senior Reporter

The CD47 field ran in­to an­oth­er hur­dle Tues­day as I-Mab qui­et­ly dis­closed in an SEC fil­ing that Ab­b­Vie is say­ing good­bye …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times